Importantly, evidence for clinical activity and objective response in some IDH mutant low-grade glioma patients has been reported (NCT02481154, NCT02746081, NCT03030066, NCT03343197) [85–89]. This evidence concerns the gene IDH1 and central nervous system cancer.